Use of dihydro myricotin element for treating cardiac blood diseases

A dihydromyricetin, cardiovascular technology, applied in the field of medicine, can solve problems such as no antithrombotic effect

Inactive Publication Date: 2007-08-29
广西中医学院
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Dihydromyricetin is a dihydroflavonol compound, its structure is similar to myricetin, and its natural resources are very rich. In recent years, studies have shown that it ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Dihydromyricetin 200g

[0015] Polyvinylpyrrolidone 31g

[0016] Microcrystalline Cellulose 150g

[0017] 130g pregelatinized starch

[0018] Sodium Lauryl Sulfate 10g

[0019] Magnesium Stearate 2.5g

[0020] Flavor Appropriate amount

[0021]

[0022] A total of 1000 pieces

Embodiment 2

[0024] Dihydromyricetin 100g

[0025] Myricetin 5-10g

[0026] Cross-linked polyvinylpyrrolidone 18g

[0027] Polyvinylpyrrolidone 15g

[0028] Microcrystalline Cellulose 58g

[0029] α-Lactose 57g

[0030] Sodium Lauryl Sulfate 5g

[0031] Magnesium Stearate 1.5g

[0032] Flavor Appropriate amount

[0033]

[0034] A total of 1000 pieces

Embodiment 3

[0036] Dihydromyricetin 200g

[0037] Myricetin 5-10g

[0038] ice flakes 2g

[0039] Polyvinylpyrrolidone 35g

[0040] Microcrystalline Cellulose 150g

[0041] 130g pregelatinized starch

[0042] Sodium Lauryl Sulfate 10g

[0043] Magnesium Stearate 2.5g

[0044] Flavor Appropriate amount

[0045]

[0046] A total of 1000 pieces

[0047] Verification of the antithrombotic effect of dihydromyricetin:

[0048] ADP-induced acute pulmonary embolism in mice and venous thrombosis in rats are commonly used animal tests to verify that drugs have antithrombotic effects. Therefore, these two methods were used to verify the antithrombotic effect of dihydromyricetin.

[0049] 1. Experimental animals: Kunming white mice, 18-22g; Wistar rats, weighing 100-135g. SPF grade animals were provided by the Experimental Animal Center of Guangxi Medical University, license number: SCXK Gui 2003-0003. The animals were kept in separate cages ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses an application of dihydromyricetin in preparation of medicine for preventing or curing angiocardiopathy. The animal tests show that the dihydromyricetin has the effect for resisting internal phlebothrombosis, can be used for effectively preventing angiocardiopathy due to thrombosis, for example cardiac disease and apoplexy. Said invention can be made into medicine or health-care product.

Description

technical field [0001] The invention relates to the technical field of medicine, and is a new application of dihydromyricetin for treating thrombus-embolic cardiovascular diseases. Background technique [0002] Thromboembolic cardiovascular disease is a disease that seriously endangers human health, and antithrombotic drugs are more effective methods for treating thromboembolic diseases. However, studies in recent years have found that the antithrombotic drugs currently used clinically can produce some side effects. For example, heparin sodium is an anticoagulant that has been used clinically for decades. In recent years, it has been found that heparin can cause immune thrombocytopenia, which can aggravate thrombotic diseases and induce new thrombosis syndromes. arouse great clinical attention. Aspirin, widely used clinically, mainly antagonizes thromboxane A 2 (TXA 2 ) has a good curative effect in the prevention and treatment of thrombotic diseases, but there are many ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P7/02A61P9/10
Inventor 覃洁萍
Owner 广西中医学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap